Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease

22 Jun 2024

Abstract excerpt

CT1812 is a novel, brain penetrant small molecule modulator of the sigma-2 receptor (S2R) that is currently in clinical development for the treatment of Alzheimer's disease (AD). Preclinical and early clinical data show that, through S2R, CT1812 selectively prevents and displaces binding of amyloid beta (Aβ) oligomers from neuronal synapses and improves cognitive function in animal models of AD. SHINE is an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alzheimer's disease research and treatments
Share to Bioinformatics and Genomic Networks
Share to Computational Drug Discovery Methods

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38914170
DOI: 10.1016/j.nbd.2024.106575

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's diseasePMID 38914170Read ↗

An interim exploratory biomarker analysis of a Phase 2 clinical trial to assess the impact of CT1812 in Alzheimer’s diseaseSemantic proximity Read ↗

CT1812 biomarker signature from a meta‐analysis of CSF proteomic findings from two Phase 2 clinical trials in Alzheimer's diseaseSemantic proximity Read ↗

CSF proteomic analysis of semorinemab Ph2 trials in prodromal-to-mild (Tauriel) and mild-to-moderate (Lauriet) Alzheimer’s disease identifies distinct trial cell-type specific proteomic signaturesSemantic proximity Read ↗

Small Molecule Agonists of TREM2 Reprogram Microglia and Protect Synapses in Human Alzheimer’s ModelsSemantic proximity Read ↗

Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins.Semantic proximity Read ↗

Dual Inhibitors Targeting G9a and GSK-3β: Translational Perspectives on Alzheimer’s Disease TreatmentSemantic proximity Read ↗

Investigating the Effects of Semaglutide in Early Alzheimer’s Disease Using Single-cell Transcriptomics and Proteomics – Rationale and Design (P12-3.017)Semantic proximity Read ↗

Oral Blarcamesine Phase IIb/III Trial Confirms Identified Precision Medicine Patient Population – Significant Broad Clinical and Quality of Life Improvements for Early Alzheimer’s Disease PatientsSemantic proximity Read ↗

Evaluation of Exploratory Fluid Biomarker Results from a Phase 1 Senolytic Trial in Mild Alzheimer’s DiseaseSemantic proximity Read ↗

CSF proteomic profiling with amyloid/tau positivity identifies distinctive sex-different alteration of multiple proteins involved in Alzheimer’s diseaseSemantic proximity Read ↗

BT-11 repurposing potential for Alzheimer’s disease and insights into its mode of actionsSemantic proximity Read ↗

SWATH-MS analysis of cerebrospinal fluid to generate a robust battery of biomarkers for Alzheimer's disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.